MarketPulse

IND submission

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Vesicor Therapeutics Appoints Veteran Biotech Executive Tolentino as CEO Ahead of SPAC Merger

Vesicor Therapeutics names Michael Tolentino as CEO effective March 2026, succeeding founder Luo Feng. Leadership transition precedes de-SPAC merger completion and 2027 FDA submission.
BKHABKHARBKHAUSPAC mergerCEO appointment
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Editas Medicine Slashes Q4 Losses While Advancing CRISPR Therapy Toward Human Trials

Editas Medicine reported Q4 2025 net loss of $5.6M, down 88% YoY. Lead CRISPR therapy EDIT-401 shows >90% LDL-C reduction; IND submission expected mid-2026.
BMYCELGrEDITclinical trialCRISPR